Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
CLOZAPINE FOR THE TREATMENT OF LEVODOPA-INDUCED PSYCHOSIS AND DYSKINESIA IN PARKINSONS-DISEASE
Autore:
JALENQUES I; COUDERT AJ;
Indirizzi:
CHU ST JACQUE,CTR MEDICOPSYCHOL,SERV PSYCHIAT A,BP 69 F-63003 CLERMONT FERRAND FRANCE
Titolo Testata:
Irish journal of psychological medicine
fascicolo: 2, volume: 11, anno: 1994,
pagine: 83 - 88
SICI:
0790-9667(1994)11:2<83:CFTTOL>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
D2-DOPAMINE RECEPTOR OCCUPANCY; ATYPICAL ANTIPSYCHOTIC-DRUGS; DOPAMINOMIMETIC PSYCHOSIS; ELECTROCONVULSIVE-THERAPY; DOPAMINE; NEUROLEPTICS; FLUPERLAPINE; D1-DOPAMINE; TREMOR;
Keywords:
CLOZAPINE; PARKINSONS DISEASE; PSYCHOSIS; DYSKINESIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social Sciences Citation Index
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
I. Jalenques e A.J. Coudert, "CLOZAPINE FOR THE TREATMENT OF LEVODOPA-INDUCED PSYCHOSIS AND DYSKINESIA IN PARKINSONS-DISEASE", Irish journal of psychological medicine, 11(2), 1994, pp. 83-88

Abstract

The treatment of psychosis in patients with Parkinson's disease (PD) is one of the most difficult problems in clinical psychiatry. Clozapine's low propensity to induce extrapyramidal side effects makes it an attractive treatment for psychotic patients with PD. A number of published uncontrolled studies suggest that low-dose clozapine is effective in these patients. However, the dose range, side effect profiles and length of treatment have varied in these reports. In this article, the authors review the literature and report on the effects of clozapine in a patient with Parkinson's disease and psychosis. Clozapine (50 mg per day) resulted in a complete resolution of psychosis, improvement ofmotor function, reduction of ''off'' time and a major improvement in levodopa-induced dystonic dyskinesias. The only adverse effect was mild sedation during the first two weeks of clozapine treatment. The lackof acute blockade of striatal D2 receptors by clozapine and the failure of chronic clozapine treatment to suppress striatal dopamine release may account for its beneficial effect in Parkinson's disease. Additionally, an ameliorating effect of clozapine on parkinsonism might be due to its action on serotonergic systems leading to release of striatal dopamine.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 04:21:16